Site-specific endonucleases can be engineered for custom recognition of any genetic locus and used for gene targeting. Yet, the prolonged expression and accumulation of these nucleases in cells lead to toxic effect. Here we describe an efficient and quantitative method for introducing nucleases into cells as proteins packaged within lentiviral vector particles. I-CreI-derived meganucleases, which can be engineered as single-chain proteins, were incorporated into lentiviral vector particles either without modification or as fusions with cyclophilin A. The small amount of nuclease delivered by the viral particles is sufficient to induce efficient targeted mutagenesis in human HEK293H and primary T cells. When a repair template sequence was packaged in the lentiviral vector, high levels of homologous gene targeting were obtained and toxicity was markedly reduced.
INTRODUCTION
Technologies for targeted genome modifications are being developed at a rapid pace. Once they can be successfully implemented into gene therapy approaches, they hold promise for enabling precise gene correction, addition or knock out for the purpose of treating diseases. Importantly, they would eliminate the safety issues associated with the current integrative gene transfer vectors and their propensity to yield uncontrolled ectopic modifications.
Most targeting methods developed for human cells are based on the use of site-specific endonucleases that create DNA doublestrand break (DSB) at or near their recognition site(s) in the genome. The cell responds to these toxic chromosomal lesions by triggering repair pathways. Depending on the cell cycle status, error-prone non-homologous end joining or homologous recombination (HR) with a cognate donor sequence will prevail. 1 Site-specific endonucleases have been engineered by associating a DNA cleavage domain with a programmable DNA recognition component made of combinations of Zinc Fingers or Transcription Activator-Like Effectors (TALE-nucleases), or of an RNA guide (CRISPR/Cas). 2 A large number of specific nucleases have also been derived from naturally occurring homing endonucleases (meganucleases, MN). 3 These tools allow modifying virtually any sequence in the human genome with variable efficiencies depending on the chromosomal location and chromatin environment. 4 Up to 50% of non-homologous end joiningmediated targeted mutagenesis (TM) by Zinc Finger in cultured human primary cells 5 and 3% homologous gene targeting (HGT) in mouse 6 have been reported. This level of efficiency supports the ongoing exploration of the technology in clinical trials. 7 DSBs are the most toxic lesions in DNA, because they trigger chromosomal rearrangements. Although a large proportion of non-homologous end joining repaired DSB is non-mutagenic and restores the original DNA sequence, 8 the sustained intracellular expression of targeting nucleases leading to iterative cutting, increases the probability of a catastrophic genotoxic event and therefore may severely limit the efficiency and safety of genetargeting procedures. In addition, designer endonucleases often display a background activity at cryptic sites in the genome, and the possibility of creating additional DSBs increases toxicity. [9] [10] [11] [12] [13] [14] [15] Limiting nuclease-associated toxicities has become a priority in the field of gene targeting. As one approach to address the problem, nucleases have been modified to allow for the cleavage of only one strand of DNA. [16] [17] [18] Single-stranded nicks are far less toxic and still enhance HGT, albeit at a two-to fivefold lower level. Second, nucleases can be made available and active transiently in the nucleus, either by controlling their sub-cellular localization by an appended nuclear receptor hormone-binding domain, [19] [20] [21] by adding drug-dependent destabilization domains 22 or by expressing them from non-integrating vectors. 2, 23 Yet, the presence of high levels of the nuclease even for a few days is often enough to cause substantial toxicity. 9, [11] [12] [13] [14] A third way to minimize chromosome exposure to a nuclease is to deliver it as a protein, which is present and active during a short-time frame. For example, the positively charged Zinc Fingers, when directly added to cultured cells as recombinant proteins, are internalized and active. 24 We and others have described methods that allow producing lentiviral vector particles containing active MNs or recombinase fused to Vpr, and shown a high efficiency of transfer into mammalian cells. 25, 26 Here we apply this approach to I-CreI-derived MNs with different ranges of targeting activities and toxicities. The nucleases are packaged into lentiviral particles either directly or as fusion with cyclophilin A (CypA), a cellular protein recruited to the viral cores through interactions with the N-terminal of the capsid (CA) protein. 27 CypA is important for directing the core into the nuclear entry pathway and ensuring integration into preferred genomic loci. 28, 29 We show that site-specific nucleases packaged into lentiviral vector virions mediate gene targeting with reduced toxicity in human cell. This mode of delivery is a simplification over existing methods because a single lentiviral vector simultaneously brings into the cell both the nuclease and donor sequences for HR. This type of vector will most likely be required for the development of direct in vivo gene-targeting procedures.
RESULTS

Incorporation of functional MNs into lentiviral particles
We have generated I-CreI-derived single-chain MNs targeting a number of candidate sites in human genome. 4 Among those, MN Chr14m (CLS4076m in Daboussi et al. 4 ) recognizes a unique sequence upstream of the Fut8 gene on human Chr14q23.3. Its initial characterization indicates a capacity to be expressed at high levels in HEK293H cells and to yield around 5% TM and 0.4% HGT. However, high intracellular levels of nuclease are associated with significant toxicity, with up to 60% cell death in a 6-day culture assay. We tested the possibility of delivering Chr14m as a protein associated with lentiviral particles, asking whether this mode of intracellular administration would alleviate toxicity. We used either CypA or Vpr to provide a tether between Chr14m and the lentiviral core. 27, 30 These were fused to the C-terminus of Chr14m using a seven amino acids linker (Figure 1a) . The stability and catalytic activity of fusions were verified after transfection in HEK293T cells ( Supplementary Figures 1 and 2 ) and in a luciferase-based extrachromosomal recombination assay (Figure 1b ). In this assay, an inactivated luciferase reporter carrying an internal duplication interrupted by the MN-targeting site can be rescued in the presence of an active MN that triggers recombination between the two repeats. 31 The C-terminal fusion with CypA retained 33-89% of the activity of Chr14m (Figure 1c) , whereas the fusion with Vpr significantly affected the activity (10-21%) and the apparent level of the protein on western blot (Supplementary Figure 1) . The endonuclease activity was also preserved in CypA fusion proteins made with three other I-CreI-derived MNs, Chr21m, Chr19m and Chr7m (Figure 1d, Supplementary Figure 2) . MN fusions were incorporated into non-integrative lentiviral vector (NILV) particles by expressing them in 293T cells during vector production (for vector nomenclature, please see Materials and methods). Western blot analysis of NILV.GFP virions ( Figure 2a ) produced with different plasmid amounts showed a dosedependent association of the Chr14mCypA fusions. Chr14mVpr was most efficiently incorporated, consistent with the fact that HIV virions contain up to 700 Vpr molecules versus 500 for CypA. 32, 33 The presence of the Chr14mCypA protein did not affect the infectivity of NILV.GFP measured on HEK293T cells, whereas a fivefold reduction was observed with Chr14mVpr ( Supplementary  Figure 3a) . The vector production was not affected by the extra plasmid (pUC18 or pUC18 plus the fusion plasmids pChr14mCypA or pChr14mVpr) added during viral packaging, but it was reduced by 1.3-to 2.2-fold when fusion protein Chr14mCypA or Chr14mVpr was expressed (Supplementary Figure 3b) . We also incorporated Chr21m, Chr19m and Chr7m as CypA fusions into NILVs and all were found associated with the virions (Figure 2b) .
The association of the Chr14mCypA fusion protein with the lentiviral particles was further characterized. When overexpressed, the VSV-G protein triggers the formation of vesicles that can trap cellular proteins and lead to protein pseudo-transduction. 34 To address this issue, the incorporation of the nuclease into NILV was also performed in the presence of an amphotropic MLV envelope protein (MLV-A) instead of VSV-G. Western blot analysis of the virions showed an efficient incorporation of the fusion protein into MLV-A pseudotyped NILV, at levels comparable to those documented using VSV-G (Figure 2c ). We concluded that the association of the MN with the vector was not envelope protein dependent.
The interaction between CypA and the HIV CA protein can be competitively blocked by cyclosporine A. 33 Virions packaged in the presence of 5 μg ml − 1 cyclosporine A contained reduced levels of the Chr14mCypA fusion protein (Figure 2d reduced activity in luciferase assay (Figure 3a) . This indicated an essential role of the CypA domain in driving the incorporation of the fusion protein into the viral particles through its interaction with CA. Finally, the nuclease-associated virions were treated with proteinase K in order to assess their localization inside the virion. 26 VSV-G, located on the virion surface, was degraded completely by proteinase K at a concentration of 0.01 mg ml − 1 ( Figure 2e ). In contrast, a significant fraction of the Chr14mCypA protein was protected, consistent with its location inside of viral particles. We next measured the site-specific endonuclease activity associated with MN-loaded virions using the luciferase assay. Second generation NILVs encoding green fluorescent protein , on Chr14mCypA incorporation into virions. (e) Sensitivity of virion-associated proteins to proteinase K digestion. VSV-G and p24 are monitored as controls for external or internal virion proteins, respectively. Different p24 signal intensities from a to e are due to different exposure time. (GFP) were prepared in the presence of MN or MN fusions and designated as NILV.GFP[MN] (see Nomenclature in Materials and methods). These MN-loaded vectors were used to transduce HEK293T cells previously transfected with the reporter luciferase construct pmtsLuc.Chr14t and luciferase activity was measured after 3 days. The amounts of rescued luciferase activity obtained with the MN fusion-containing NILV were compared with a positive control in which the MN was encoded by the NILV. When the Chr14mCypA fusion protein was associated to the NILV (NILV.GFP[Chr14mCypA]), the vector displayed up to 50% of positive control activity (Figure 3b ). In addition, when NILV.GFP [Chr14mCypA] virions were prepared with increasing amounts of fusion protein expression plasmid, their potency was enhanced accordingly. A dose response study with increasing amounts of NILVs in the luciferase assay indicated that the activity was correlated to the amount of virions used (1 pg of p24 is equivalent to 1.25 × 10 4 lentiviral particles). The Chr14mVpr fusion, despite its more efficient incorporation, was less active than CypA fusion (o 30%). Other CypA fusions for Chr21m, Chr19m and Chr7m diplayed 45%, 27% and 22% of control activities, respectively (data not shown).
In order to rule out an artifactual activity due to plasmid DNA contaminating the lentiviral preparation, the vectors were treated with Benzonase before performing the HR assay. The luciferase activity generated with the NILV.GFP Figure 5b) . All vectors were prepared using the same packaging conditions, always in the presence of the Tat protein, which is therefore unlikely to contribute to the differences observed. The vectors NILV.GFP[Chr14m] and NILV.HR Chr14t [Chr14m] packaged with the presence of the plasmid expressing unmodified Chr14m were also tested and no toxicity was detected compared with the control. In comparison, transduction with the conventional expressing vector NILV.Chr14m was associated with up to 70% of cell death above dose 0.45 pg p24 per cell and increased apoptosis. NILV.GFP [Chr14mCypA] co-packaged using 20 μg of fusion plasmid was associated with 5.6% apoptosis (Supplementary Figure 5c) . The reduced toxicity is likely due to the comparatively low amounts of MN delivered into cells as a single bolus, which were below the limit of detection of MN antibodies by western blot after transduction (data not shown). The short time-course of MN protein presence in cells is another potential reason for the reduced toxicity. However, it is also possible that altered activity levels of the CypA fusion compared with the native proteins can affect cytotoxicity.
Chromosomal targeting in HEK293H cells and primary T cells NILV.HR Chr14t [Chr14mCypA] were tested for their ability to mediate HGT at the unique chromosomal target recognized by the nuclease. A vector genome containing sequences (around 250 bp for either right or left homologous arms) flanking the Chr14m target site separated by a 30 bp tag was assembled and packaged without or with the Chr14mCypA fusion protein (NILV. HR Chr14t or NILV.HR Chr14t [Chr14mCypA], respectively). HEK293H cells were transduced for 3 days, seeded in 96-well plates at 10 cells per well, and grown to confluence. DNA was prepared from each well and targeting events were detected by PCR with a forward primer located in the 30 bp tag and a reverse primer beyond the 3′ homology arm on the chromosome (Supplementary Figure 6) . As expected, no HGT events were detected when NILV.HR Chr14t was used along with NILV. GFP or an irrelevant MN-coding vector (NILV.Chr19m). In contrast, a HGT rate of 1.6% was detected with NILV.HR Chr14t [Chr14mCypA] vector at the dose of 0.15 pg p24 per cell ( TM was monitored in the absence of donor sequences. PCR products from the targeted locus were obtained 3 days after NILV treatment and analyzed by deep sequencing. At the dose of 0.75 pg p24 per cell, higher TM rates were observed for NILV. Chr14m-positive control (3.80%) than for NILV.GFP[Chr14mCypA] (1.40%; Table 2 ).
Lentiviral protein delivery was evaluated in human primary T cells. T cells were isolated from blood and stimulated with anti-CD3 and anti-CD28 antibodies for 2 days and then transduced with the control vector NILV.Chr14m or NILV.GFP[Chr14mCypA] for 3 days. The transduction efficiency of T cells at day 3 monitored with an independent NILV.GFP vector was 30.8%, 50.4% and 64.0% using doses of 0.75, 2.25 and 4.5 pg p24 per cell, respectively. The infectivity of NILV.Chr14m, NILV.GFP [Chr14mCypA] and NILV.GFP in T cells was comparable with 4.2, 3.8 and 3.6 copies of viral genome per cell, respectively, using dose 2.25 pg p24 per cell. As shown in Table 2, TM rate (Figure 4a ). Proteinase K treatment indicated that a fraction of the MN protein was located inside the virions (Figure 4b ). When tested in the luciferase recombination assay in HEK293T cells, NILV associated with Chr14m, Chr21m, Chr19m or Chr7m generated 10, 38, 14, or 21% of the activity of their respective controls (Figure 4c ). Protein transfer was also observed with MLV-A pseudotyped NILVs (Supplementary Figure 7) . Chr14t [Chr14m]) were tested for HGT in 293H cells. It was not detectable at 0.15 pg p24 per cell but a transduction dose of 0.75 pg p24 per cell led to 6.0% HGT (mean of two experiments) and no observable cell toxicity (cells grew in more than 90% of the wells), which was consistent with the viability and apoptosis data in Figures 3c and d . With a transduction dose increased to 2.25 pg per cell, no cell toxicity was observed, whereas 20.6% HGT was achieved (Table 1 , mean of three experiments using two independent vector preparations). The positive samples were confirmed by PCR amplifying the entire Chr14t site with primers outside of the left and right homology arms of the donor vector followed by second round PCR with the primer specific to the donor vector, which ensure that the amplified sequence came from the locus (see Materials and methods). Therefore, NILV.HR Chr14t [Chr14m] was able to trigger exceptionally high HGT levels, despite its low activity in the luciferase assay. It is likely that these high HGT resulted from the much reduced toxicity of the protein transduction procedure, which allowed cells containing targeting events to survive throughout the experiment. Consistent with this notion, when the non-toxic nuclease Chr19m was evaluated for chromosomal targeting (using vector NILV.HR Chr19t ), it was well tolerated by cells and yielded up to 14.6% HGT when coded by NILV (2.25 pg p24 per cell), 9.1% when introduced as CypA fusion protein and 2.6% when introduced as an unmodified protein. In this case, where cell toxicity did not bias the data, the difference in activity measured in the short-term luciferase assay (Figure 4c ) was also observed in the HGT assay.
Having established that very low amounts of nuclease were able to mediate efficient HGT, we asked whether higher recombination rates could be obtained when the conventional coding vector NILV.Chr14m is maintained at a low and non-toxic dose (0.15 pg p24 per cell), whereas the donor vector amount is increased. Using 2.25 pg p24 per cell NILV.HR Chr14t donor vector, HGT was increased to 5.2%, compared with the 1.9% shown in Table 1 . It seems that toxicity reduction is not the sole reason for the high HGT efficiency mediated by NILV. HR Chr14t [Chr14m]. The amount of donor sequences available is another limiting factor.
DISCUSSION
The goal of this study was to obtain a simple method for the delivery of site-specific nucleases into human cells that would reduce toxicity without affecting gene-targeting efficiency. We have packaged I-CreI-derived MNs into lentiviral vector particles, and we show that they are delivered through the viral entry pathway and that they mediate gene targeting in human cells including primary T cells. We assume that providing the nuclease as a protein allows it to remain for a limited time only, minimizing potential toxicity. We show that active MNs can be incorporated into lentiviral particle either without modification or by fusing them to proteins known to be abundant in the virion such as Vpr or CypA. MNs lend themselves to this method of delivery because they can be produced as a single-chain molecule. Zinc Finger and TALE-nucleases are mostly available as heterodimers and their packaging in a lentiviral virion therefore represent an additional challenge.
We have observed that fusion with Vpr markedly reduces MN activity and vector infectivity. CypA, a protein chaperone with a peptidyl prolyl isomerase activity and the most abundant of ubiquitously expressed cyclophilins, therefore stands out as the preferred fusion partner. Binding of CypA to the HIV CA occurs on one side of its eight-stranded antiparallel β barrel, leaving the N-and C-terminus available for fusions on the opposite side. We show that MNs with a C-terminal CypA fusion are active (Figures 1c and d) , strongly associated with lentiviral vectors (Figure 2a ) and do not affect their infectivity (Supplementary  Figure 3a) . The packaging of MN was demonstrated using second generation (NILV.GFP[Chr14mCypA], tat dependent) as well as third generation (NILV.HR Chr14t [Chr14mCypA], tat independent) vector packaging systems, with a tendency for higher levels of incorporation in the Tat-independent system (Supplementary Figure 5b) . CypA fusions get incorporated into the virions by competing out endogenous CypA expressed in the packaging cells, and the total amount of CypA per virion is kept approximately constant (data not shown). Most of the active fusion proteins reside in fully formed virions rather than associated with CA protein aggregates and enter the cell through the infection pathway, as indicated by the fact that a functional envelope is required for activity. In addition, we note that the CypA domain may influence the activity of the MN, as it has been reported to display chromatin tethering activity. 28 Although we show that the method is applicable to a variety of MNs, we have focused our study on Chr14m, which has a unique recognition site on human chromosome 14. When expressed in human cells by DNA transfection or with a coding lentiviral vector, Chr14m is synthesized at high levels and displays a robust activity but it is associated with significant toxicity. 4 The off-site cleaving properties of Chr14m have not been determined, but they are likely to be present as in any other engineered targeted nuclease, and to contribute to this toxicity. We show here that when Chr14m is introduced as an NILV-associated protein, both TM and HGT activities are conserved but toxicity is readily reduced (Figures 3c and d) .
Although extra-chromosomal assays involving single-strand annealing recombination are useful for a rapid monitoring of nuclease activity, they are often not predictive of their efficiency on a natural chromosomal target. 4 Following transient transfection, a very high number of nuclease target sequences are present and actively transcribed in the cell nucleus, in contrast to chromosomal targets. In addition, cell toxicity may require more than the 72-h period of the transient assay to become conspicuous. 4 Thus, TM measured 3 days after transduction is higher with NILV.Chr14m than with NILV.GFP[Chr14mCypA] because more MN is introduced by the coding vector. We suggest that toxicity does not affect the measure of TM, which is done early, but does have important effect in the HGT assay in which cells are grown for 2-3 weeks. As a consequence, protein transduction results in higher and more reproducible scores in the HGT assay.
A variety of cellular proteins are known to be packaged in lentiviral virions through interactions with proteins (that is, CypA) or lipids (that is, APOBEC3G) and have important roles in viral infection. Although we have not investigated the mechanism, we show here low amounts of MN without fusion partners consistently associate with lentiviral particles. Using our standard NILV doses (0.75 pg p24 per cell), these low amounts of protein result in as many HGT events as when the conventional vector is used, if not more so. As these preparations are devoid of cellular toxicity, we have been able to increase the dose up to 2.25 pg p24 per cell and we have observed HGT rates above 20%. Our interpretation is that the high activity of Chr14m at creating DSBs does not readily translate into high levels of chromosomal HR because high level of nuclease is toxic and a large proportion of targeted cells are eliminated. Only when a brief pulse of the protein is delivered, can the high efficiency of the MN be revealed in the HGT assay.
Intermediate toxicity is observed with the CypA fusion protein delivery method at high doses (Figures 3c and d and Table 1 ). However, the dose of protein delivered to cells can be adjusted by changing the level of fusion encoding plasmid in the lentiviral vector-packaging system (Figure 2a) , and depending on the characteristics of the nuclease, it is possible to define conditions for high efficiency and low toxicity. This is much more difficult to achieve when the nuclease is expressed in the target cell, even for a few days only.
The method we describe here offers the possibility of adjusting the amount of site-specific nuclease delivered into cells, in order to avoid toxicity and optimize efficiency. Lentiviral vectors are able to enter a wide variety of cells in primary cultures or in situ following in vivo delivery. Nuclease-loaded vectors also transferring donor sequences for HR should be of general use for safe multiplex genome editing and therapeutic applications requiring direct in vivo genome modification.
MATERIALS AND METHODS
Plasmid constructions
pmtsLuc reporter plasmids. Four mutations (T214A, I232A, F295L and E354K) were introduced in the firefly luciferase-coding sequence from pGL4.51 (Promega, Madison, WI, USA) to generate a thermostable enzyme. 36 The reporter plasmid pmtsLuc.Chr14t was constructed by duplication of the DraIII to BpmI luciferase fragment (position 1150-1359, Supplementary Figure 9 ). pmtsLuc.Chr14t was obtained by inserting in between the repeats a PCR fragment generated from pmtsLuc with the following primers: forward 5′-ACTGGGTGCTCGAGTTGTAATGTCTTACAAG GTTTTAACGCGGCGAGCTGTG-3′ (underlined Chr14m target sequence) and reverse 5′-GCGGAAGAGCGCCCAATAC-3′ and digested with XhoI and BamHI. The reporter plasmid pmtsLuc.Chr21t (target sequence 5′-TTA ATACCCCGTACCTAATATTGC-3′ on human Chr21q21.1), pmtsLuc.Chr19t (target sequence 5′-CAGGGCCGCGGTGCAGTGTCCGAC-3′ on human Chr19q13.42) and pmtsLuc.Chr7t (target sequence 5′-GATGGCCATGGTAAG CAGGAGGGC-3′ on human Chr7q35) were constructed using the same strategy.
Fusion protein expression plasmids. The human CypA-coding sequence was fused to the C-terminus of Chr14m in plasmid pChr14m. 4 First, Chr14m with C-terminal fusion sequence (CFS) was amplified from pChr14m using a forward primer located in CMV promoter (5′-CGCAAATGGGCGGTAGG CGTG-3′) and a reverse primer located at the C-terminus of Chr14m with CFS extension (5′-CTGAGACTGTGAGGGCAGTTCTGGATTCGTTAACTAAGT CTAAAATCTCCGGATAGCTCGAGTTCGAG-3′). The region between the two primers in plasmid pChr14m was replaced with the PCR product using the BssHII and XhoI restriction sites. CypA sequences (507 bp) were inserted between BspE1 and XhoI sites at the C-terminus of CFS in plasmid pChr14m-CFS to generate plasmid pChr14mCypA, which expresses the fusion protein Chr14mCypA. Vpr (334 bp) fusion plasmid (pChr14mVpr), pChr21mCypA, pChr19mCypA and pChr7mCypA were constructed using similar strategies. The CypA cDNA was a kind gift from GJ Towers (University College London, London, UK).
Lentiviral vectors.
The plasmid pRRL-Chr14m was obtained by inserting a SalI-NheI fragment containing the CMV promoter and the Chr14m sequence from pChr14m between the cPPT and WPRE elements in the plasmid pRRLSIN-cPPT-PGK-MCS-WPRE 37 (XhoI-NheI). The plasmids pRRLChr21m, pRRL-Chr19m and pRRL-Chr7m were constructed using the same protocol. The plasmid pLV.HR Chr14t was constructed by insertion of a HR donor sequence with a 30-bp insertion (Supplementary Figure 10) replacing PGK-MCS-WPRE in the plasmid pRRLSIN-cPPT-PGK-MCS-WPRE (tat independent). pHRSIN.CSGW (expressing GFP, tat dependent), p8.91/D116A and phCMV-A-MLV were provided by Dr E Verhoeyen, Dr A Cimmareli and Dr F-L Cosset (Ecole Normale Superieure de Lyon, Lyon, France).
Incorporation of MNs into NILV
HEK293T cells (2.6 × 10 6 ) were seeded in 10 ml of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin/ streptomycin in a 10-cm dish and transfected after 24 h using calcium phosphate co-precipitates. The NILV.GFP vector, a second-generation lentiviral vector whose production is dependent on the presence of HIV Tat, was prepared by mixing in 375 μl To compare the infectivity of NILV.Chr14m and NILV.GFP[Chr14mCypA] in T cells, DNA was extracted 3 days after transduction and the copies of viral genome was determined by quantitative PCR on long terminal repeat and albumin. The primers for long terminal repeat amplification are forward 5′-AGCTTGCCTTGAGTGCTTCAA-3′ and reverse 5′-AGGGTCTGAGG GATCTCTAGTTACC-3′. Primers for albumin are forward 5′-GCTGTCATC TCTTGTGGGCTGT-3′ and reverse 5′-ACTCATGGGAGCTGCTGGTTC-3′.
Luciferase assay HEK293T cells were seeded in 96-well plate at 1.7 × 10 4 cells per well in 100 μl medium (Dulbecco's modified Eagle's medium, 10% fetal bovine serum and 1% penicillin/streptomycin). JetPEI Polyplus reagent (Ozyme, St Quentin Yvelines, France) was used the next day to transfect cells with 75 ng pmtsLuc reporter along with 75 ng of plasmid DNA composed of carrier pUC18 and 0, 0.4, 1.6, 6.25 or 25 ng of MN expression plasmid. Alternatively, the seeded cells were transduced with NILVs (in triplicate wells) after transfection with 75 ng pmtsLuc reporter along with 75 ng of pUC18. After 3 days, luciferase activity was determined with the Promega luciferase assay system. Luminescence was measured in counts per second in a Perkin Elmer Victor X3 plate reader, and normalized to 1 μg of total cell lysate protein quantified by Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL, USA). For the Benzonase treatment, 1 U of benzonase (SigmaAldrich, St Louis, MO, USA) was added to 50 μl concentrated vectors and incubated for 30 min at 37°C before used for cell transduction.
Western blot for detecting incorporation of MN fusion in NILV particles
Identical amounts of lentiviral vectors (30 ng p24) were denatured at 95°C in loading buffer, migrated in 10% SDS-polyacrylamide gel and then transferred to a poly(vinylidene fluoride) membrane (GE Healthcare Life Science, Little Chalfont, UK). Fusion proteins were detected with a polyclonal antibody against I-CreI (1:1000 dilution, developed in rabbit by Cellectis, Paris, France). P24 antibody was from NIH AIDS Research. VSV-G antibody was from Sigma-Aldrich. For proteinase K protection assay, concentrated vectors (30 ng) were treated for 10 min at room temperature with 0.005 or 0.01 mg ml − 1 of proteinase K followed by addition of the serine protease inhibitor phenylmethylsulphonyl fluoride (1 mM final concentration) and heating for 10 min at 90°C before SDS-polyacrylamide gel electrophoresis and blot.
Apoptosis detection by propidium iodide staining HEK293T cells were seeded in 96-well plates at 1.7 × 10 4 cells per well in 100 μl Dulbecco's modified Eagle's medium and infected one day later with NILVs. After 3 days of transduction, one-tenth of cells were re-seeded and culture was continued for 4 days. Cells were trypsinized, harvested and resuspended in Hank′s buffer, then fixed with cold ethanol at 4°C for longer than 24 h. The cells were spun down, resuspended in buffer (45 mM Na 2 HPO 4 , 2.5 mM citric acid, 0.1% Triton X-100, pH 7.8), stained with staining buffer (10 mM PIPES or piperazine-N,N′-bis(2-ethanesulfonic acid), 100 mM NaCl, 2 mM Mg 2 Cl, 0.2% Triton X-100, 50 μg ml − 1 propidium iodide, 50 U ml − 1 RNAse, pH 6.8) and analyzed by flow cytometry. Cell viability was calculated by forward scatter/side scatter parameter in fluorescenceactivated cell sorting analysis.
HGT assay HEK293H cells were seeded in 0.5 ml Dulbecco's modified Eagle's medium in 24-well plates (5 × 10 4 cells per well), transduced after 24 h with vectors for 3 days and then trypsinized and re-seeded in 96-well plates (10 cells per well or 3 cells per well for two cases). The transduction efficiency with a dose of 0.15 pg p24 per cell was above 90% monitored with an independent transduction control using NILV.GFP. After 2-3 weeks, genomic DNA was prepared using ZR-96 Quick-gDNA kit (ZYMO research, Irvine, CA, USA) and eluted in 40 μl buffer. Five microliters of the DNA were used for positive HGT detection by PCR with primers 5′-TTAAGGCGCGC CGGACCGCGGC-3′ and 5′-CTGGACCATGTGACTGACTAGC-3′ and 30 thermal cycles of 95°C 30 s, 58°C 30 s and 72°C 1 min. The schematic of the donor construct and a targeted event showing the location of the detecting primers and a representative picture of PCR result was shown (Supplementary Figure 6) . In the HGT assay mediated by NILV. HR Chr14t [Chr14m], the positive samples were confirmed by PCR amplifying the entire Chr14t site with primers (forward 5′-TTGCAGACTCGGTTCATCTG-3′, reverse 5′-GCCAATAAATGGGTTCCCTAA-3′) outside of the left and right homology arms of the donor vector followed by second round PCR with the primer specific to the donor vector, which ensure that the amplified sequence came from the locus (Supplementary Figure 8) . The PCR product of the first PCR was not purified before the second round PCR. Supplementary Table shows for each condition the number of wells analyzed, the number of clones growing per well and the number of positive wells in all the experiments. The HGT rate was calculated by the percentage of positive wells from total wells analyzed divided by the average number of clones per well growing from the seeded cells.
Deep sequencing for TM detection HEK293H were transduced with vectors in 24-well plate with 5 × 10 4 cells per well in 500 μl medium for 3 days. Primary T cells were isolated from human blood with lymphoid cell enrichment kit RosetteSep HLA (StemCell Technologies, Vancouver, BC, Canada), stimulated with anti-CD3/CD28-coated plate for 2 days, then transduced with vectors in 48-well plate with 1 × 10 5 cells per well in 300 μl of RPMI 1640, 10% fetal bovine serum, 1% penicillin and streptomycin and 3 ng ml − 1 hIL2 for 3 days. After transduction, cells were harvested and genomic DNA was extracted using DNease Blood and Tissue kit (Qiagen, Hilden, Germany).
A 450-bp fragment containing Chr14m target site was amplified by PCR from purified genomic DNA. The forward primer 5′-TTCAGGTTAGGTGAC CTTCAAACTGGGG-3′ is linked to 5′ sequencing primer 5′-CCATCTCATCC CTGCGTGTCTCCGAC-3′ and tags (5′-CTACGCTCTA-3′, 5′-CTATAGCGTA-3′, 5′-TACGTCATCA-3′, 5′-TAGTCGCATA-3′ or 5′-TATATATACA-3′). Reverse primer is 5′-AAGACCAGGCTGGGCAACCATAGCAAG-3′ with 5′ extension 5′-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3′. The PCR products were isolated from agarose gel and extracted, then further purified with Agencout AMPure XP kit (Beckman Coulter, Brea, CA, USA) before being sequenced. Amplicon sequencing was performed using a 454 system (454 Life Sciences, Brandford, CT, USA) with an average of 1000 sequence reads per sample analyzed. Non-homologous end joining events were considered if insertions or deletions were detected within 2 bp of the expected cleavage site. The TM% is the percentage of total insertions/ deletions. All mutations falling outside of the targeted sequence or mutations of 1 bp inside the targeted site were not taken into account.
Statistics
The differences between two groups were analyzed using unpaired, homoscedastic Student's t-test. Error bars indicate standard error of mean (s.e.m.).
NOMENCLATURE
Chr14m, Chr21m, Chr19m, or Chr7m: meganuclease whose targeting site is on chromosome 14, 21, 19 or 7.
Chr14t, Chr21t, Chr19t, or Chr7t: targeting sequence of Chr14m, Chr21m, Chr19m or Chr7m.
Chr14mCypA: C-terminal fusion of meganuclease Chr14m with CypA.
